Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

(E) -Daporinad

Catalog No: tcsc1055

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg

Specifications

CAS No:
658084-64-1

Formula:
$C_{24}H_{29}N_3O_2$

Pathway:
Metabolic Enzyme/Protease;Autophagy

Target:
Nampt;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 50 mg/mL (127.71 mM)

Alternative Names:
FK866;APO866

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
391.51

Product Description

FK866 is an effective inhibitor of nicotinamide phosphoribosyltransferase (**NMPRTase**) with an **IC_{50}** of 0.09 nM.

IC50 & Target: IC50: 0.09 nM (NMPRTase)

In Vitro: Nampt inhibition with FK866 induces significant NAD^+ intracellular reduction and selectively kills MM cells. FK866-induced cell death is associated with inhibition of Nampt activity, rather than protein expression, and higher NAD^+ baseline levels in MM cells than normal PBMCs confer FK866 sensitivity. FK866 abrogates the survival advantage conferred by the bone marrow microenvironment[1]. FK866 prevents the $[Ca^{2+}]$i increase induced by different mitogens and reduces the Ca^{2+} content of TG-responsive Ca^{2+} stores in Jurkat and in activated PBLs. FK866 reduces the Ca^{2+} content of TG-responsive Ca^{2+} stores in Jurkat cells but not in Bcl2-Jurkat cells[2]. Inhibition of NAMPT by FK866, or inhibition of SIRT by nicotinamide decreases proliferation and triggered death of 293T cells involving the p53 acetylation pathway[3].

In Vivo: FK866 (30 mg/kg, i.p.) decreases the tumor burden in CB17-SCID mice, and the tumor tissue demonstrates a significant decrease in ERK phosphorylation and proteolytic cleavage of LC3[1].